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http://dx.doi.org/10.1016/j.ccr.2013.11.007SUMMARYRecruitment of tumor-associated macrophages (TAMs) into avascular areas sustains tumor progression;
however, the underlying guidance mechanisms are unknown. Here, we report that hypoxia-induced
Semaphorin 3A (Sema3A) acts as an attractant for TAMs by triggering vascular endothelial growth factor
receptor 1 phosphorylation through the associated holoreceptor, composed of Neuropilin-1 (Nrp1) and
PlexinA1/PlexinA4. Importantly, whereas Nrp1 levels are downregulated in the hypoxic environment,
Sema3A continues to regulate TAMs in an Nrp1-independent manner by eliciting PlexinA1/PlexinA4-medi-
ated stop signals, which retain them inside the hypoxic niche. Consistently, gene deletion of Nrp1 in
macrophages favors TAMs’ entrapment in normoxic tumor regions, which abates their pro-angiogenic
and immunosuppressive functions, hence inhibiting tumor growth and metastasis. This study shows
that TAMs’ heterogeneity depends on their localization, which is tightly controlled by Sema3A/Nrp1
signaling.INTRODUCTION
Inflammatory / immune responsesmostly involve the recruitment
of circulating monocytes to specific locations, such as intra-
tumoral areas, bacterial entry sites, arthritic joints, infarcted
lesions, or atherosclerotic plaques (Eltzschig and Carmeliet,
2011). In particular, macrophages infiltrating the tumor, named
tumor-associated macrophages (TAMs), represent the most
abundant stromal component of many cancer types and the
presence of extensive TAM infiltration, often but not always,
correlates with poor prognosis in a variety of human carcinomasSignificance
TAM infiltration of human cancers was reported to correlate w
antitumoral. Here, we show that TAMs’ localization into hyp
signaling axis, leading to PlexinA1/PlexinA4-dependent VEGF
arrested because of Nrp1-independent PlexinA1/PlexinA4-me
normoxic regions by blunting the Sema3A/Neuropilin-1 pathw
overall inhibiting tumor growth and metastasis. These results
with tumor hypoxia and suggest alternative approaches to h
within the tumor, and thus their phenotype.
Ca(De Palma and Lewis, 2013; Johansson et al., 2008). This is
because TAMs entail protumoral functions, but they were also
reported to be antitumoral (Biswas and Mantovani, 2010; Cous-
sens et al., 2013; Johansson et al., 2008). Such opposed TAM
phenotypes occupy distinct niches in the tumor, thus raising
the question whether this may reflect ‘‘education’’ of the macro-
phages by specific signals in the tumormicroenvironment and/or
whether TAM subsets might derive from distinct macrophage
precursors (Murdoch and Lewis, 2005).
Neuropilin-1 (Nrp1) was originally identified as a receptor for
class-3 semaphorins controlling neuronal guidance and axonalith opposed prognoses because TAMs can be either pro- or
oxic tumor areas is controlled by a Sema3A/Neuropilin-1
R1 activation. Once in the hypoxic environment, TAMs are
diated stop signals. We found that confining TAMs inside
ay restores anti-tumor immunity and abates angiogenesis,
underscore the predictive value of macrophage association
ijack TAMs against cancer by modulating their localization
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Nrp1 in Tumor-Associated Macrophagesgrowth (Gu et al., 2003; Kolodkin et al., 1997). Besides playing
a decisive role in the developing nervous system, Nrp1 is
expressed in a variety of non-neural cells and can modulate mul-
tiple physiological and pathological processes (Gerhardt et al.,
2004; Gu et al., 2003; Hayashi et al., 2012; Liang et al., 2007;
Soker et al., 1998). Preclinical data suggest that blockade of
Nrp1 suppresses tumor growth by inhibiting angiogenesis or
by impairing survival and proliferation in a variety of cancer cell
types (Hong et al., 2007; Liang et al., 2007; Pan et al., 2007).
Nrp1 is also widely expressed in lymphoid and myeloid cells
(Bruder et al., 2004; Fantin et al., 2010; Pucci et al., 2009).
In vitro and in vivo studies have identified a regulatory role of
this molecule in immune responses, cell proliferation, chemo-
taxis, and cytokine production of T cells and dendritic cells
(DCs) (Catalano, 2010; Catalano et al., 2006; Delgoffe et al.,
2013; Hansen et al., 2012; Takamatsu et al., 2010; Tordjman
et al., 2002). Other studies, also from our laboratory, have
described Nrp1 as a marker of pro-angiogenic and pro-arterio-
genic macrophages in physiological and pathological conditions
(Fantin et al., 2010; Pucci et al., 2009; Rolny et al., 2011; Takeda
et al., 2011). Nevertheless, the functional relevance of this mole-
cule in macrophages is not known.
By using genetic tools and several tumor mouse models, we
study how Nrp1 controls TAMs’ entry into hypoxic regions in
response to its ligand Semaphorin 3A.
RESULTS
Loss of Nrp1 in Macrophages Inhibits Tumor
Progression
By intercrossing Nrp1 floxed mice with LysM-Cre mice, we
generated LysM-Cre;Nrp1L/L mice where Nrp1 expression is
reduced by 92% in TAMs and 81% in their monocyte precursors,
but less than 60% in tumor-associated neutrophils (TANs) or
DCs (Figure S1A available online). Compared to littermate con-
trols (LysM-Cre;Nrp1+/+; wild type [WT] in short), LysM-
Cre;Nrp1L/L mice were normal and had similar blood counts
(Table S1 and Fantin et al., 2013); however, the implantation of
subcutaneous Lewis lung carcinomas (LLC) resulted in 60%
smaller tumors and 55% fewer pulmonary metastases (Figures
1A–1C). Tumor apoptosis was increased in LysM-Cre;Nrp1L/L
mice (Figure S1B) but proliferation was unchanged (Figure S1C).
Tumor vessel area, density and branching points, together with
vessel perfusion, were strongly decreased in LysM-Cre;Nrp1L/L
mice (Figures 1D–1I).
To achieve specific deletion of Nrp1 in macrophages, but not
in other myeloid cells (Figure S1D and Qian et al., 2011), we
intercrossed Nrp1 floxed mice with the tamoxifen-inducible
iCSF1R-Cre line, thus generating iCSF1R-Cre;Nrp1L/L mice.
Acute deletion of Nrp1 shortly before LLC tumor injection,
abated tumor growth, metastasis, and vessel formation to a
similar extent as in LysM-Cre;Nrp1L/L mice (Figures 1J–1L;
Figures S1E and S1F). Thus, Nrp1 loss in TAMs inhibits cancer
progression and angiogenesis.
Loss of Nrp1 in TAMs Prevents Their Entry into Hypoxic
Niches
To quantify tumor infiltration of myeloid cells in WT and LysM-
Cre;Nrp1L/Lmice, we stained tumor sections for the pan-myeloid696 Cancer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc.marker CD11b. Tumors in LysM-Cre;Nrp1L/L mice were infil-
trated with almost twice more myeloid cells than in the con-
trols (Figures S1G–S1I). Among all the CD11b+ myeloid cells,
only TAMs, but not TANs or DCs, were more abundant
in LysM-Cre;Nrp1L/L versus WT mice (Figures 1M–1O; Fig-
ure S1J). Increased TAM density was not associated to a
difference in the frequency of total circulating monocytes or
monocyte subsets (‘‘inflammatory’’ CD115+Ly6Chigh versus
‘‘resident’’ CD115+Ly6Clow monocytes), TAM proliferation, or
TAM apoptosis (Figures S1J–S1M). Moreover, in a model of
acute skin inflammation, macrophage infiltration was equally
induced in both genotypes, suggesting that Nrp1 deletion did
not affect monocyte recruitment or their differentiation into
macrophages (Figure S1N).
We reasoned that the rise of TAMs in LysM-Cre;Nrp1L/L mice
was due to increased tumor hypoxia (Eltzschig and Carmeliet,
2011; Murdoch and Lewis, 2005), possibly resulting from
reduced tumor perfusion. Indeed, the hypoxic tumor area was
2.2-times higher in LysM-Cre;Nrp1L/L than in WT mice (Figures
1P and 1R). Conversely, at early stages (when tumor volume
and weight were comparable in both genotypes), the amount
of hypoxic areas as well as TAMs did not change (Figures
S1O–S1R), suggesting that increased TAM infiltration in LysM-
Cre;Nrp1L/L mice was secondary to tumor progression and
augmented hypoxia. Consistently, hypoxia-induced monocyte
attractants such as Ccl2, Csf1, and Csf2 were comparable in
both genotypes at short term, but they were higher in LysM-
Cre;Nrp1L/L mice at the end stage, the time point when TAMs’
frequency increases in thesemice (Figures S1S–S1U). Strikingly,
in LysM-Cre;Nrp1L/L mice, TAMs were found mostly in normoxic
(PIMO-negative) regions, and their accumulation inside hypoxic
areas was instead greatly prevented both at early (Figure S1V)
and end stage (Figures 1S–1U). In LysM-Cre;Nrp1L/L mice as
well, total hypoxic area and total density of TAMs in end-stage
tumors were augmented but TAM accumulation within the
hypoxic regions was reduced (Figures 1V–1X). Apoptosis and
proliferation of WT and Nrp1-knockout (KO) TAMs or bone
marrow-derived macrophages (BMDMs), cultured in either nor-
moxia (21% O2) or hypoxia (1% O2) for 36 hr, did not differ (not
shown). Altogether, these data indicate that Nrp1 is not directly
involved in macrophage recruitment to the tumor but might
rather be involved in TAM entry into hypoxic niches.
TAM Redistribution by Nrp1 Loss Hinders Orthotopic
and Spontaneous Tumors
Because the microenvironment strongly influences tumor
responses (Blouw et al., 2003), we evaluated how Nrp1 loss
in TAMs affected the progression of several orthotopic tumors.
First, we injected LLC cancer cells directly in the lungs.
Sixteen days after injection, 47% of WT mice and only 8%
of LysM-Cre;Nrp1L/L mice died (Figure 2A). Of all the survivors,
whole lung weight in WT mice was 63% higher than in LysM-
Cre;Nrp1L/L mice and tumor expansion in WT mice completely
destroyed the structure of the pulmonary parenchyma
whereas this was better preserved in LysM-Cre;Nrp1L/L mice
(Figures 2B–2D).
Because pancreatic cancers expressing higher VEGF or
Sema3A levels haveworse prognosis (Biankin et al., 2012;Mu¨ller
et al., 2007; Niedergethmann et al., 2002), we injected Panc02
Figure 1. Loss of Nrp1 in TAMs Inhibits Their Entry into Hypoxic Niches
(A–C) Subcutaneous LLC tumor growth (A), weight (B), and lungmetastases (C) inmice withmyeloid cell-specific deletion ofNrp1 (LysM-Cre;Nrp1L/L; L/L in short)
and controls (LysM-Cre;Nrp1+/+; WT in short).
(D–F) Tumor vessel area (D), density (E), and perfusion (F) in WT and LysM-Cre;Nrp1L/L (L/L) mice.
(G–I) Vessel branching quantification (G) and micrographs (H and I) on CD31-stained LLC tumor thick-sections.
(J–L) Subcutaneous LLC tumor growth (J), lung metastases (K), and tumor vessel density (L) in mice with macrophage-specific deletion of Nrp1 (iCSF1R-
Cre;Nrp1L/L; L/L in short) and controls (iCSF1R-Cre;Nrp1+/+; WT in short).
(M–O) F4/80 quantification (M) andmicrographs (N andO) showing TAM infiltration of end-stage subcutaneous LLC tumors inWT and LysM-Cre;Nrp1L/L (L/L) mice.
(P–R) Quantification (P) and micrographs of pimonidazole (PIMO)-stained LLC tumor sections in WT and LysM-Cre;Nrp1L/L (L/L) mice (Q and R).
(S–U) Morphometric quantification (S) and micrographs (T,U) of LLC tumor sections stained for F4/80 and PIMO, showing TAM infiltration of hypoxic tumor
regions in WT and LysM-Cre;Nrp1L/L (L/L) mice.
(V–X) Tumor hypoxia (V) and TAM infiltration of the overall tumor sections (W) or of hypoxic tumor regions (X) in WT and iCSF1R-Cre;Nrp1L/L (L/L) mice.
All experiments, n = 8. *p < 0.05 versus WT. Scale bars: 100 mm. All graphs show mean ± SEM. See also Figure S1 and Table S1.
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Nrp1 in Tumor-Associated Macrophagespancreatic cancer cells orthotopically in WT and LysM-
Cre;Nrp1L/L mice. Also in this case, end-stage tumor weight
was reduced by 60% in LysM-Cre;Nrp1L/L versus WT mice
(Figure 2E). The number of metastatic lymph nodes in the mes-
entery of LysM-Cre;Nrp1L/L mice was two times lower than
that found in WT mice (Figure 2F).
To prevent inflammation caused by technical procedures (i.e.,
needle injection), we intercrossed WT and LysM-Cre;Nrp1L/L
mice with mice expressing the PyMT oncoprotein under the con-
trol of themousemammary tumor virus promoter (MMTV-PyMT),
a mousemodel that spontaneously develops multiple metastaticCamammary gland carcinomas (Lin et al., 2003). In this genetic
background, tumors reached end stage in 22-week-old control
mice. LysM-Cre;Nrp1L/L littermates had 50% smaller tumors
(Figures 2G–2I). Although the overall tumor incidence did not
differ between genotypes, LysM-Cre;Nrp1L/L mice displayed
more hyperplastic and intraepithelial neoplastic lesions but
fewer early and late carcinomas (Figures 2J and 2K). Further-
more, lung metastases in these mice were 80% less than those
in controls (Figure 2L).
Similar to what observed in subcutaneous LLC tumors, all
these orthotopic models displayed higher tumor hypoxia andncer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc. 697
Figure 2. Loss of Nrp1 in TAMs Abates Orthotopic Tumor Growth and Metastasis
(A–D) Kaplan-Meier at 16 days (n = 11-17; A), lung weight (B), and pulmonary structure by hematoxylin and eosin staining (C and D) in WT and LysM-Cre;Nrp1L/L
(L/L) mice orthotopically implanted with LLC tumors (n = 7).
(E and F) Orthotopic Panc02 tumor weight (E) and number of metastatic mesenteric lymph nodes (F) in WT and LysM-Cre;Nrp1L/L (L/L) mice. n = 9.
(G–J) Total tumor volume (G), total (H) andmean (I) tumor weight, and tumor incidence (J) inWT and LysM-Cre;Nrp1L/L (L/L) mice intercrossed with amouse strain
developing spontaneous breast cancer (PyMT). n = 14.
(K) Frequency of hyperplastic (Hyp) or intraepithelial (Min) neoplastic mammary lesions compared to the frequency of early (EC) or late (LC) PyMT mammary
carcinomas.
(L) Number of lung metastatic nodules arising from PyMT tumors.
(M–R) Hypoxic PIMO+ areas (M–O) and TAM accumulation (P–R) in the indicated tumor model.
(S–U) Quantification and representative images of TAMs in PIMO+ regions in the indicated tumor model.
(V) Tumor vessel area in the indicated tumor model.
*p < 0.05 versus WT. Scale bars: 100 mm. All graphs show mean ± SEM.
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Nrp1 in Tumor-Associated MacrophagesTAM infiltration in LysM-Cre;Nrp1L/L than in WT mice (Figures
2M–2R); however, Nrp1-KO TAMs failed to enter hypoxic niches
(Figures 2S–2U). This phenotype was associated with reduced
tumor vascularization (Figure 2V). Altogether, these data show
that TAM redistribution by loss of Nrp1 is accompanied by a
slower progression of several orthotopic tumors independently
from their tissue of origin.
TAMRedistribution byNrp1 LossRestores Immunity and
Reduces Angiogenesis
Because TAMs in LysM-Cre;Nrp1L/L mice failed to enter hypox-
ic tumor regions, we studied the effect on their phenotype.698 Cancer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc.Compared to WT TAMs, TAMs from LysM-Cre;Nrp1L/L mice
were less potent in promoting endothelial cell (EC) migration
and in inducing the formation of EC capillary networks, either
when co-cultured directly with ECs or upon stimulation of
ECs with TAM-conditioned media (Figures 3A–3E; Fig-
ure S2A–S2D). Furthermore, TAMs from LysM-Cre;Nrp1L/L
mice released more nitric oxide (NO; Figure 3F), were more
cytotoxic against cancer cells (Figure 3G), and displayed
reduced T cell suppression (thus increasing T cell proliferation;
Figure 3H). Notably, all these functions did not differ between
WT and Nrp1-KO BMDMs (Figures 3A–3C and 3F–3H; Figures
S2A and S2B), suggesting that the different distribution of
Cancer Cell
Nrp1 in Tumor-Associated MacrophagesTAMs in LysM-Cre;Nrp1L/L mice, not Nrp1 loss per se, strongly
affects their phenotype.
The in vitro effects of Nrp1-KO TAMs on ECs are in agree-
ment with the reduced tumor vessel density/area and
vascular complexity observed in LysM-Cre;Nrp1L/L mice.
Because Nrp1-KO TAMs also had a milder T cell immunosup-
pressive capacity, we analyzed how this translated in vivo.
The frequency of CD4+ T helper cells (Th) in subcutaneous
LLC tumors was similar in both genotypes whereas intratu-
moral CD8+ cytotoxic T lymphocytes (CTLs) were 1.6-times
more abundant in LysM-Cre;Nrp1L/L than in WT mice (Figures
3I–3L). Despite their comparable numbers, CD4+ lymphocytes
in LysM-Cre;Nrp1L/L mice displayed higher expression of
antitumoral Th1 markers (Figure 3M). Enhanced CTL recruit-
ment and Th1 T cell skewing, following Nrp1 loss in myeloid
cells, was also observed in PyMT spontaneous breast tumors
(Figure 3N). This pronounced Th1/CTL response was associ-
ated with an enriched expression of antitumoral M1 genes
and decrease of some protumoral M2 markers in TAMs
sorted from LysM-Cre;Nrp1L/L mice (Figures 3O–3V). How-
ever, these genes were equally expressed in cultured WT
and Nrp1-KO BMDMs, either at baseline (in normoxia or hyp-
oxia) or under forced M1/M2-skewing conditions (Figures
S2E–S2L), suggesting that the M1 profile of Nrp1-KO TAMs
was secondary to microenvironmental changes in the tumor
(see below).
When administering anti-CD4 and anti-CD8 antibodies, alone
or in combination, depletion of Th cells and/or CTLs in LysM-
Cre;Nrp1L/L mice mildly (but not significantly) increased growth
and weight of subcutaneous LLC tumors compared to tumors
treated with an isotype IgG (Figures 4A and 4B). In contrast,
depletion of Th cells or CTLs in LysM-Cre;Nrp1L/L mice resulted
in accelerated LLC tumor growth, reaching comparable sizes
as tumors in WT mice (Figures 4A and 4B). Depletion of both
CD4+ and CD8+ T cells had similar effects as depletion of
CD8+ T cells alone, indicating that CTLs are the main effectors
of tumor inhibition in LysM-Cre;Nrp1L/L mice (Figures 4A and
4B). The efficiency of intratumoral CD4+ cell depletion was
almost complete in both WT and LysM-Cre;Nrp1L/L mice, and
anti-CD8 antibodies did not affect the frequency of Th cells in
both genotypes (Figure 4C). Conversely, tumor-infiltrating
CTLs were 2.3 times more abundant in LysM-Cre;Nrp1L/L
versus WT mice, but they were reduced by 40%, 90%, and
96%, respectively, following anti-CD4, anti-CD8, or combined
treatment (Figure 4D). Circulating CD4+ and CD8+ cell numbers
did not differ in both WT and LysM-Cre;Nrp1L/L mice, and treat-
ment with anti-CD4 and/or anti-CD8 antibodies depleted these
cells from the bloodstream almost completely in both geno-
types (Figure S3). Reduction of tumor vessel area and density
in LysM-Cre;Nrp1L/L mice was independent from Th cells
and/or CTLs (Figures 4E and 4F). Instead, the excess of M1-
like TAMs in LysM-Cre;Nrp1L/L mice was abrogated, partly,
by Th cell depletion and, completely, by CTL depletion
(Figure 4G).
These data demonstrate that inhibition of TAMs’ entry into
hypoxic niches hinders their angiogenic and immunosuppres-
sive potential while fostering Th1 cells and CTLs, which, in
turn, will sustain macrophage cytotoxicity and adaptive anti-
tumor immunity.CaNrp1 Is Transcriptionally Repressed in Hypoxic
Macrophages
Finally, we studied how Nrp1 could be mechanistically involved
in TAM positioning inside the hypoxic regions. First, we deter-
mined how oxygen tension affects Nrp1 expression in macro-
phages. In BMDMs, Nrp1 transcripts were reduced by 80% in
hypoxia compared to normoxia (Figure 5A). Similarly, freshly iso-
lated hypoxic (PIMO-positive) TAMs expressed 90% less Nrp1
than the normoxic (PIMO-negative) counterpart (Figure 5B).
The efficiency of gene deletion was complete in both normoxic
and hypoxic BMDMs or TAMs isolated from LysM-Cre;Nrp1L/L
mice (Figures 5A and 5B). Also in tumor sections, Nrp1 was
almost undetectable in WT TAMs localized within hypoxic
(PIMO-positive) areas; as expected, Nrp1 staining was always
negative in TAMs from LysM-Cre;Nrp1L/L mice (Figure 5C). In
contrast, the hypoxia-responsive gene Flt1 (encoding vascular
endothelial growth factor receptor 1 [VEGFR1]) was 5-fold
induced in hypoxic versus normoxic BMDMs or TAMs, and
Nrp1 deletion did not affect this regulation (Figures 5D and 5E).
We then measured the expression of Sema3a and Vegfa in
hypoxic (PIMO-positive) and normoxic (PIMO-negative) tumor
single cell suspensions that contain cancer cells and stromal
cells. Both genes were upregulated in the hypoxic fraction of
the tumor (Figures 5F and 5G). Consistently, both Sema3a and
Vegfa were induced in LLC cancer cells cultured in hypoxia
(1% O2; Figures 5H and 5I).
When seeking the molecular mechanisms underlying hypoxic
repression ofNrp1 in macrophages, we found that gene deletion
of Hif2a but not Hif1a completely abrogated this downregulation
(Figure 5J). In particular, HIF-2 only was entirely responsible for
the hypoxic induction of Ikbkg and, in good part, of Ikbkb,
together forming the IKK complex, required for the activation
of the canonical NF-kB pathway (Figures 5K and 5L), which
can repressNrp1 (Hayashi et al., 2012). Indeed, genetic inactiva-
tion of this pathway in Ikbkb-KO macrophages prevented Nrp1
downregulation by hypoxia; overexpression of p50/p65 NF-kB
subunits in Hif2a-KO or Ikbkb-KO macrophages restored this
transcriptional repression (Figure 5J). These data indicate that
hypoxic stabilization of HIF-2 in macrophages unleashes the ca-
nonical NF-kB pathway via IKK induction. Consequently, release
of active p50/p65 heterodimers blocks Nrp1 expression.
Nrp1 Regulation by Hypoxia Defines Macrophage
Responses to Sema3A
Prompted by the above observations, we assessed the chemo-
tactic potential of Sema3A or VEGF on WT and Nrp1-KOmacro-
phages, isolated respectively from WT and LysM-Cre;Nrp1L/L
mice. In the presence of Sema3A, migration of WT BMDMs
was doubled whereas Nrp1-KO BMDMs did not respond.
VEGF164 was equally potent but the absence of Nrp1 decreased
this migratory response by only 30%. Thus, Nrp1 is strictly
necessary for macrophage attraction by Sema3A, but not by
VEGF164. Indeed, VEGF120 (which does not bind Nrp1 effectively;
Soker et al., 1998) was as good as VEGF164 in attracting bothWT
and Nrp1-KO BMDMs (Figure 6A). In line with the migratory
phenotype, Sema3A and VEGF164 induced cytoskeleton remod-
eling and macrophage elongation; however, while the absence
of Nrp1 completely abrogated Sema3A activity, it marginally
reduced the response to VEGF164 (Figure S4A).ncer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc. 699
Figure 3. Exclusion of Nrp1-KO TAMs from Hypoxic Areas Prevents Their Angiogenic Phenotype and Restores Their Antitumor Features
(A–E) Histograms showing HUVEC migration toward BMDMs or TAMs isolated fromWT or LysM-Cre;Nrp1L/L (L/L) mice (A), and HUVEC organization (in red), as
measured by their branch number (B) and total network length (C) in co-culture with TAMs (D and E).
(F–H) Nitric oxide (NO) release (F), cytotoxicity on thymidine-labeled LLC cancer cells (G), and T cell suppression (H) by BMDMs or TAMs.
(legend continued on next page)
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Figure 4. TAM Redistribution by Nrp1 Loss Favors T Cell-Mediated Antitumor Immunity
(A and B) Subcutaneous LLC tumor growth in WT (A, left) and LysM-Cre;Nrp1L/L (L/L) mice (A, right), and their end-stage tumor weights (B), following systemic
administration of CD4 and CD8 neutralizing antibodies, alone or in combination.
(C and D) Efficiency of Th cell (C) or CTL (D) depletion in the tumors.
(E and F) Quantification of vessel area (E) and vessel density (F) on LLC tumor sections.
(G) Quantification of F4/80+MRC1 M1-like TAM infiltration on LLC tumor sections.
All experiments, n = 6–8. *p < 0.05 versus IgG control. All graphs show mean ± SEM. See also Figure S3.
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Nrp1 in Tumor-Associated MacrophagesSimilar results were obtained in vivo, where subcutaneous
matrigel plugs containing recombinant Sema3A, VEGF164, or
VEGF120 displayed a strong and comparable macrophage infil-
tration. Loss ofNrp1 reduced macrophage attraction to Sema3A
by 50% and to VEGF164 by 20% only, whereas VEGF120 activity
did not change (Figure 6B).
Because Sema3A and VEGF164 are present together in the
tumor and are both induced by hypoxia, we assessed in vitro
macrophage migration in response to combined Sema3A and(I) FACS quantification on single cell LLC tumor suspensions of CD4+ Th cells an
(J–L) Quantification (J) and micrographs (K and L) of CD8-stained LLC tumor sec
(M and N) Expression of Th1 (Ifng, Il12, Il2, Cxcl11) and Th2 (Il4, Il10, Il6, Ccl17) g
PyMT tumors (N) in LysM-Cre;Nrp1L/L (L/L) mice, normalized to the expressions
(O–V) Expression of the M1 markers Nos2 (O), Cxcl9 (P), Il12 (Q), Cxcl10 (R), an
subcutaneous LLC tumors.
All experiments, n = 6–12. *p < 0.05 versusWT; #p < 0.05 versus BMDMs. Scale ba
Figure S2.
CaVEGF164 under either normoxia or hypoxia (1%O2). Interestingly,
in normoxia, this combination did not further increase the migra-
tion of WT macrophages compared to either cytokine alone,
whereas Nrp1-KO macrophages further lost their migratory
response to VEGF (Figure 6C). In hypoxia, neither WT nor
Nrp1-KO macrophages were attracted toward Sema3A (con-
sistent with hypoxia-mediated and genetic-driven Nrp1 loss,
respectively); conversely, their response to VEGF164 was even
stronger than in normoxia (Figure 6D), likely because ofd CD8+ cytotoxic T lymphocytes (CTLs).
tions.
enes in tumor-infiltrating CD4+ Th cells sorted from subcutaneous LLC (M) or
in WT controls.
d the M2 markers Arg1 (S), Ym1, (T), Il10 (U), Ccl22 (V) in TAMs sorted from
rs: 50 mm (D and E) and 25 mm (K and L). All graphs showmean ± SEM. See also
ncer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc. 701
Figure 5. Hypoxic Repression of Nrp1 in Macrophages Is Mediated by HIF2-Dependent NF-kB Activity
(A) Nrp1 expression in BMDMs derived from WT and LysM-Cre;Nrp1L/L (L/L) mice and cultured in normoxia (21% O2; NRX) or hypoxia (1% O2; HPX).
(B) Nrp1 expression in normoxic (PIMO) or hypoxic (PIMO+) TAMs (E) directly sorted from WT and LysM-Cre;Nrp1L/L (L/L) mice.
(C) Quantification and representative micrographs of Nrp1+F4/80+ TAMs in normoxic (PIMO) or hypoxic (PIMO+) tumor areas.
(D and E) Flt1 expression in normoxic (NRX) or hypoxic (HPX) BMDMs (D) and in normoxic (PIMO) or hypoxic (PIMO+) TAMs (E).
(F and G) Sema3a (F) or Vegfa (G) induction in hypoxic (PIMO+) versus normoxic (PIMO) tumor cell bulks from either WT or LysM-Cre;Nrp1L/L (L/L) mice.
(H and I) Sema3a (H) and Vegfa (I) expression in cultured LLC cancer cells.
(J)Nrp1 transcript levels inWT,Hif1a-KO (Hif1aL/L),Hif2a-KO (Hif2aL/L), and Ikbkb-KO (IkbkbL/L) BMDMs, electroporatedwith a control (Ctrl) plasmid (on the left) or
with two plasmids overexpressing the NF-kB subunits p50 and p65 (on the right), and cultured under normoxic (NRX) or hypoxic (HPX) conditions.
(K and L) Ikbkb (K) and Ikbkg (L) expression in normoxic (NRX) and hypoxic (HPX) WT, Hif1a-KO (Hif1aL/L), Hif2a-KO (Hif2aL/L) BMDMs.
n = 8 in (A–G) and n = 4 in (H–L). *p < 0.05 versus WT controls; #p < 0.05 versus NRX or PIMO+. Scale bars: 100 mm. All graphs show mean ± SEM.
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hypoxic macrophages (either WT or Nrp1-KO) was barely
induced upon combined stimulation with Sema3A and VEGF164
(Figure 6D).
These data suggest a Nrp1-independent function of Sema3A
antagonizing VEGF-induced attraction and prompted our search
for evidence that Sema3A can interact with macrophages even
in the absence of Nrp1. Cell-binding experiments in situ with
alkaline-phoshatase (AP) tagged molecules demonstrated that
Sema3A binding is also remarkably present on Nrp1-KO cells702 Cancer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc.(about 50% less than in WT cells), as validated by specific
competition by unlabeled Sema3A (Figure 6E). Thus, Sema3A
can specifically interact with Nrp1-KO macrophages, potentially
accounting for the functional activity observed in hypoxic
conditions.
The chemokine CCL21 can elicit macrophage egression from
tumor hypoxic niches because its levels are much higher in nor-
moxic versus hypoxic cancer cells (Figure S4B). Remarkably,
Sema3A significantly reduced the migration toward CCL21 of
Nrp1-KO or hypoxicWTmacrophages, whereNrp1 is also barely
Figure 6. Sema3A Attracts or Retains Macro-
phagesDepending on the Presence or Absence
of Nrp1
(A) Migration of WT and Nrp1-KO (L/L) BMDMs toward
Sema3A, VEGF164, or VEGF120.
(B) Migration of F4/80+ macrophages in subcutaneous
matrigel plugs supplemented with Sema3A, VEGF164,
or VEGF120.
(C and D) Migration of WT and Nrp1-KO (L/L) BMDMs
toward Sema3A and VEGF164, alone or in combination,
under normoxic (NRX; C) or hypoxic (HPX; D) condi-
tions.
(E) Binding of Sema3A-AP (or Sema3E-AP as control)
to WT and Nrp1-KO (L/L) BMDMs in absence or
presence of 2-foldmolar excess of unlabeled Sema3A.
Cell-bound AP activity was revealed in situ using
colorimetric reactions as shows in micrographs.
(F and G) Migration of WT and Nrp1-KO (L/L) BMDMs
toward Sema3A and VEGF164, alone or in combination,
under normoxic (NRX; F) or hypoxic (HPX; G) condi-
tions.
*p < 0.05 versus WT; #p < 0.05 versus mock. Scale
bars: 100 mm in (A), 50 mm in (B), and 20 mm in (E). All
graphs show mean ± SEM of four independent
experiments. See also Figure S4.
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Figure 7. TAM Attraction by Sema3A Involves VEGFR1, whereas Their Retention Requires PlexinA1/A4 Only
(A and B) Western blot (A) and densitometry (B) for VEGFR1 Y1213 phosphorylation in WT and Nrp1-KO (L/L) BMDMs upon Sema3A and VEGF stimulation.
(C) Migration toward Sema3A or VEGF164 of WT and Nrp1-KO (L/L) BMDMs silenced for Flt1 (siFlt1) or scramble control (shCtrl).
(D and E) VEGFR1 phosphorylation (D) and migration (E) in Sema3A-treated WT and Nrp1-KO (L/L) BMDMs, upon silencing of Plxna1, Plxna2, Plxna4, or Plxnd1.
(F) Migration of WT and Nrp1-KO (L/L) BMDMs toward Sema3A and VEGF164, alone or together, upon combined silencing of Plxna1 and Plxna4.
*p < 0.05 versus WT; #p < 0.05 versus mock. All graphs show mean ± SEM of three to four independent experiments. See also Figure S5.
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the conclusion that, while Sema3A attracts macrophages in a
Nrp1-dependent manner, it is still active and can convey a
migration-inhibitory effect upon Nrp1 downregulation in the
same cells.
Sema3A Activates Opposite Signaling in Presence or
Absence of Nrp1
Semaphorins are mainly known as repelling signals, acting
through receptors called plexins. However, when plexins trans-
activate receptor tyrosine kinases (RTKs), semaphorin signals
can be converted into attractive cues (Tamagnone, 2012). At
least in one case, this was found to implicate the expression of
Nrp1 (Bellon et al., 2010). While studying Sema3A-mediated
activation of RTKs in macrophages, we found that Sema3A
induced VEGFR1 Tyr1213 phosphorylation more potently than704 Cancer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc.VEGF164 itself. Loss of Nrp1 in macrophages completely abro-
gated Sema3A-dependent VEGFR1 activation without signifi-
cantly affecting the response to VEGF (Figures 7A and 7B).
We then knocked down VEGFR1 in both WT and Nrp1-KO
BMDMs (Figure S5A) and assessed the biological consequences
on Sema3A-mediated migration. Whereas Nrp1 was largely
dispensable for the migratory response toward VEGF164, the
knockdown of VEGFR1 entirely prevented the migration of both
WT and Nrp1-KO macrophages in response to either Sema3A
or VEGF164. This suggested that Nrp1 requires VEGFR1 to trans-
duce Sema3A-mediated attractive signals, whereas VEGFR1
alone can mediate VEGF activity in macrophages (Figure 7C).
We then evaluated the expression of plexins known to form
semaphorin holoreceptors in association with Nrp1, namely
PlexinA1, PlexinA2, PlexinA3, PlexinA4, and PlexinD1 (Tamag-
none, 2012). All these plexins, except PlexinA3, were detectable
Cancer Cell
Nrp1 in Tumor-Associated Macrophagesin TAMs and BMDMs and equally expressed in both WT and
Nrp1-KO cells (Figures S5B and S5C). Silencing of PlexinA1 or
PlexinA4 (but not of PlexinA2 or PlexinD1) in WT BMDMs
(Figure S5D) abrogated Sema3A-mediated VEGFR1 phosphory-
lation and migration as potently as genetic deletion of Nrp1
(Figures 7D and 7E). These cells were still migrating in response
to serum stimulation, confirming their viability (Figures S5E
and S5F).
Moreover, upon costimulation with Sema3A and VEGF,
silencing of PlexinA1 and PlexinA4 prevented the migratory
blockade orchestrated by Sema3A in Nrp1-KO BMDMs (Fig-
ure 7F). Thus, in presence of Nrp1, a Sema3A/PlexinA1/PlexinA4
axis mediates attractive cues via VEGFR1 transactivation, which
are reverted into stop signals in the absence of Nrp1.
Sema3A Defines TAM Positioning within the Tumor
To assess the specific role of Sema3A in vivo, we used two com-
plementary strategies. First, we used Nrp1Sema- knock-in (KI)
mice, which have a disrupted Sema3A-Nrp1 binding site that
leaves VEGF165-Nrp1 binding unaffected (Gu et al., 2003). As
expected, Nrp1Sema- macrophages did not migrate toward
Sema3A whereas they responded normally to either VEGF164
or VEGF120 (Figure 8A). Compared to control mice (WT/WT),
WT recipient mice transplanted with bone marrow (BM) cells
fromNrp1Sema- mice (KI/WT) displayed tumor growth inhibition
and decreased vessel area and density, accompanied by
increased tumor hypoxia and macrophage infiltration (Figures
8B–8G). Importantly, Nrp1Sema- TAMs failed to enter hypoxic
tumor regions, thus resembling the overall phenotype observed
in tumor-bearing LysM-Cre;Nrp1L/L mice (Figure 8H).
Second, we established subcutaneous tumors by injection of
Sema3A-silenced LLC (LLC-Sh3A) or scrambled controls (LLC-
ShCtrl) in WT and LysM-Cre;Nrp1L/L mice. Sema3a knockdown
was 85% in normoxia and completely prevented hypoxic induc-
tion of Sema3a (Figure S6A). In vitro proliferation of LLC-Sh3A
and LLC-ShCtrl was comparable (Figure S6B). However, LLC-
Sh3A tumors in WT mice displayed growth and vessel inhibition,
as well as TAM exclusion from hypoxic areas, to a similar extent
as LLC-ShCtrl tumors in LysM-Cre;Nrp1L/L mice. Yet, Sema3A
silencing did not further affect these parameters in LysM-
Cre;Nrp1L/L mice (Figures 8I–8N). All these data indicate that
cancer cell-derived Sema3A, not VEGF, is responsible for TAM
entry into hypoxic niches through Nrp1 signaling.
DISCUSSION
Several hypotheses have proposed how TAMs might be re-
cruited to and retained in the hypoxic tumor microenvironment,
including hypoxia-mediated upregulation of chemoattractants
and downregulation of chemokine receptors (Murdoch and
Lewis, 2005). We describe a mechanism whereby Nrp1 in mac-
rophages is dispensable for their recruitment from the blood-
stream but necessary for TAM positioning in hypoxic niches.
Because macrophages differentiate from extravasated circu-
lating monocytes, TAMs will initially accumulate in the proximity
of the vascularized and perfused niche. From there, they will then
move toward avascular/hypoxic areas of the tumor where they
presumably clear necrotic cell debris.We now show that hypoxia
upregulates Sema3A and VEGF, and these signals act asmacro-Caphage attractants by inducing, respectively, Nrp1-dependent or
Nrp1-independent VEGFR1 transactivation (Figure 8O). Once
macrophages localize in the hypoxic area, Nrp1 expression in
TAMs is downregulated terminating their migratory response to
Sema3A, and therefore they remain entrapped on site. Notably,
TAMs expressing a Nrp1 mutant that cannot bind Sema3A (but
that still retains its ability to bind VEGF) fail to enter the hypoxic
regions of the tumor similarly toNrp1-KO TAMs. These data indi-
cate that VEGF signaling is not sufficient to drive TAM localiza-
tion into hypoxic areas and support the idea of the presence of
inhibitory signals able to blunt TAM attraction by VEGF and other
factors (such as CCL21). We found that Sema3A itself can play
such a role upon downregulation of Nrp1 expression in TAMs
by mediating plexin-dependent stop signals. Further work will
define if the mechanism proposed by our study holds true in
other pathologies. For instance, Nrp1 in macrophages is not
required for developmental angiogenesis (not shown and Fantin
et al., 2013), likely because the expression of its ligand Sema3A
starts later during embryogenesis (Pu¨schel et al., 1995).
Whereas Nrp1 has been considered amajor component of the
Sema3A receptor complex in association with plexins, we report
an Nrp1-independent specific binding of Sema3A to macro-
phages, deploying inhibition of chemotactic signaling via Plex-
inA1/A4 effectors. X-ray crystallographic analyses demonstrated
that Sema3A carries the same structural features enabling other
semaphorins to directly interact with plexins and trigger their
inhibitory signals (Janssen et al., 2012; Nogi et al., 2010). Howev-
er, this association seems to require the stabilizer function of
additional ligand-binding components, commonly identified in
Nrp1. In the absence of Nrp1, Sema3A binding is reduced but
not abrogated, consistent with our observations in macro-
phages. Previous reports illustrated the interaction between
Sema3A and chondroitin-sulfate glycosaminoglycans on the
plasmamembrane (DeWit et al., 2005). The punctate distribution
of these molecules at the cell surface is indeed reminiscent of
that observed for Sema3A bound to neuronal cells (De Wit
et al., 2005) and, in our study, tomacrophages. Thismay suggest
a role for proteoglycans in Sema3A receptor complexes found in
macrophages, in association with plexins, similar to what is
known for other cell guidance cues and soluble factors (de Wit
and Verhaagen, 2007; Fuster and Esko, 2005).
TAMs in avascular/hypoxic areas represent a deadly combina-
tion because TAMs respond to hypoxia with an altered gene
expression profile leading to the development of a distinct protu-
moral phenotype that favors angiogenesis, metastasis, and
suppresses antitumor immune responses (Burke et al., 2003;
Doedens et al., 2010; Movahedi et al., 2010). Here, we formally
prove that accumulation of TAMs in normoxic regions and their
exclusion from hypoxic tumor regions (upon loss of Nrp1) blunt
their angiogenic and immunosuppressive capacity, resulting in
reduced vessel branching and Th1/CTL-mediated antitumor im-
mune responses. The release of cytokines, such as interferon
gamma (IFNg), by Th1 T cells and especially by CTL will polarize
the newly recruited TAMs in M1-like cytotoxic macrophages,
thus initiating a feed-forward loop that enhances antitumor
immunity (Biswas and Mantovani, 2010; Coussens et al., 2013;
Johansson et al., 2008). Reduced angiogenesis and tumor perfu-
sion will also initiate a feed-forward loop because the resulting
hypoxia will lead to more TAM recruitment (Eltzschig andncer Cell 24, 695–709, December 9, 2013 ª2013 Elsevier Inc. 705
Figure 8. Sema3A Defines TAM Positioning within the Tumor
(A) Migration of WT and Nrp1Sema- (KI) BMDMs in response to Sema3A, VEGF164, or VEGF120.
(B and C) Growth (B) and weight (C) of subcutaneous LLC tumors injected in mice transplanted with BM from WT or Nrp1Sema- mice (WT/WT and KI/WT,
respectively).
(legend continued on next page)
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TAMs will not enter the hypoxic niches because of lack of Nrp1,
and this will perpetuate their antitumor phenotype. These find-
ings might explain some observations in human tumor biopsies
where higher numbers of TAMs do not always correlate with a
worse prognosis but rather with a favorable disease outcome
or the clinical correlation between different TAM localizations
and patient survival (De Palma and Lewis, 2013).
Different from what occurs in macrophages, Sema3A-medi-
ated Nrp1 signaling acts as a restrictive signal for EC migration
(Serini et al., 2003) and exogenous delivery of Sema3A in tumor
models can inhibit angiogenesis and hinder tumor growth
(Casazza et al., 2011; Maione et al., 2009, 2012). Notably, in
these previous studies, TAM distribution into tumors had not
been tested. Moreover, while guidance cues such as Sema3A
are known to organize cell migration and neurite extension in a
topographically controlled manner, their exogenous delivery
into tissues may elicit pharmacological effects overwhelming
the functional complexity of the endogenous signals. Indeed,
the formation of a vascular network is a dynamic process that
depends on pro-angiogenic and anti-angiogenic stimuli (Maz-
zone et al., 2009). Once recruited to the tumor from the blood-
stream, TAMs will be attracted from perivascular/normoxic into
avascular/hypoxic niches by Sema3A via an Nrp1/PlexinA1/A4/
VEGFR1 signaling platform. Downregulation of Nrp1 arrests
TAMs in their position through Nrp1-independent Sema3A-
mediated PlexinA1/A4 signals. Here, TAMs secrete ‘‘angiokines’’
such as VEGF and Sema3A, and matrix metalloproteases
including MMP2 and MMP9 (Movahedi et al., 2010; Murdoch
and Lewis, 2005; Pucci et al., 2009). ECswill thus follow themac-
rophages into the hypoxic regions of the tumor, where they are
attracted by VEGF, but their migration will be partly limited by
Sema3A-repelling signals, as Nrp1 expression in ECs is induced
by hypoxia, in contrast to macrophages (Ottino et al., 2004;
Zhang et al., 2001). Future studies will elucidate how Nrp1 is
inversely regulated by hypoxia in different cellular contexts.
The reported ability of Sema3A-Nrp1 signaling to guide TAM
migration into hypoxic niches, where they eventually are entrap-
ped, is reminiscent of the activity of axonal guidance cues
featuring navigation ‘‘go’’ and ‘‘stop’’ signals at distinctive sites,
depending on the level of signaling components (Guthrie, 1999;
Nawabi et al., 2010; Schwarz and Ruhrberg, 2010). To prove the
functional relevance of this specificmechanism in vivo, we selec-
tively inhibited Sema3A binding to Nrp1 in macrophages or we
silenced Sema3A in cancer cells, and found that, consistent
with preventing TAMmigration into hypoxic niches, this reduced(D–F) Tumor vessel area (D), tumor vessel density (E), and tumor hypoxia (F) in W
(G) Histological quantification of F4/80+ TAM accumulation in WT/WT and KI/
(H) Quantification and micrographs showing F4/80+ TAMs in PIMO+ hypoxic tum
(I–N) Growth (I), weight (J), CD31+ vessel area (K), PIMO+ hypoxic area (L), tota
derived from Sema3A-silenced LLC (Sh3A) or from scramble control LLC (ShCtr
(O) VEGF and Sema3A attract TAMs from peri-vascular (normoxic) areas to ava
independently of Nrp1, Sema3A-mediated VEGFR1 activation requires Nrp1 as
retains TAMs inside the hypoxic niche through PlexinaA1/A4 signaling. Hypoxic
contributes to tumor growth andmetastasis. Because of loss of Sema3A binding to
not attract but rather entraps TAMs in the perivascular (normoxic) areas counteri
Normoxic TAMs are then less angiogenic and more antitumoral.
n = 4 in (A), n = 10 in (B–H), and n = 6–8 in (I–N). *p < 0.05 versusWT; #p < 0.05 versu
Caangiogenesis and tumor growth. Overall, our results and the pre-
vious works show that localized activity of endogenous Sema3A
in individual cell populations versus pharmacological administra-
tion of exogenous Sema3A can have divergent effects on tumor
growth in vivo. Interestingly, antibodies selectively blocking
Sema3A binding to Nrp1, despite their scarce activity on ECs
in vitro, inhibit angiogenesis and vessel remodeling in vivo with
a similar efficacy as antibodies blocking VEGF binding to Nrp1,
thus possibly implying the effective blockade of other pro-angio-
genic cells such as macrophages (Pan et al., 2007).
Consistent with the finding that Sema3A can mediate attrac-
tive or repulsive cues, its expression has been associated with
both tumor progression (Biankin et al., 2012; Mu¨ller et al.,
2007) and tumor suppression (Maione et al., 2009; Yacoub
et al., 2009); however the functional relevance of the endoge-
nous molecule in adult tissues has not been fully elucidated.
Our study sheds light on the role of Sema3A/Nrp1 signaling in
the guidance of macrophages into hypoxic niches. Thus,
Sema3A expression in tumors may also predict the ability to
drive TAMs toward hypoxic niches to escape antitumor immunity
and to promote vascularization.
EXPERIMENTAL PROCEDURES
More detailed methods can be found in the Supplemental Experimental
Procedures.
Tumor Models
LLC cells were injected subcutaneously (2 3 106 cells) or orthotopically (1 3
106 cells); Panc02 was injected into the tail of the pancreas (1 ± 106 cells).
PyMT tumors were classified as before (Lin et al., 2003). All mouse procedures
were approved by the Institutional Animal Care and Research Advisory Com-
mittee of the K.U. Leuven.
BM Transplantation
Lethally irradiated C56BL/6 mice (9.5 Gy) were intravenously injected with 107
BM cells fromNrp1Sema- mice. Tumor experiments were initiated 6 weeks after
BM reconstitution.
Western Blot and Immunochemistry
Protein extraction was performed using extraction buffer (20 mM Tris HCl,
150mMNaCl, 1%Triton X-100, 10%glycerol, and 5mMEDTA). Immunostain-
ing protocols and hypoxia detection were performed as before (Mazzone et al.,
2009). Tumor perfusion was assessed with intravenous injection of 0.05 mg
lectin-FITC.
FACS Analysis and Flow Sorting of Tumor-Associated Cells
LLC subcutaneous tumors were minced in RPMI medium containing 0.1%
collagenase type I and 0.2% dispase type I (30 min at 37C), passed throughT/WT and KI/WT mice.
WT mice.
or regions.
l F480+ TAM accumulation (M), and hypoxic TAM accumulation (N) in tumors
l), injected subcutaneously in WT and LysM-Cre;Nrp1L/L (L/L) mice.
scular (hypoxic) niches through VEGFR1 transactivation. While VEGF works
well as PlexinA1 and PlexinA4. Upon repression of Nrp1 by hypoxia, Sema3A
TAMs acquire an immunosuppressive and pro-angiogenic phenotype, which
Nrp1 inNrp1Sema- (KI) TAMs or gene deletion inNrp1-KO TAMs, Sema3A does
ng attraction by VEGF or other cytokines in a PlexinA1/A4-dependent manner.
s mock. Scale bars: 100 mm. All graphs showmean ± SEM. See also Figure S6.
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Nrp1 in Tumor-Associated Macrophagesa 19 G needle, and filtered. After RBC lysis, cells were resuspended in fluores-
cence-activated cell sorting buffer (PBS containing 2% fetal bovine serum and
2mMEDTA) and incubatedwithMouse BD FcBlock purified antimouseCD16/
CD32 mAb (BD PharMingen), followed by staining with anti-F4/80, CD3, CD4,
CD8, CD115, Ly6C, Ly6G, CD11c, CD11b, and MRC1 for 20 min at 4C.
F4/80+ TAMs were sorted from subcutaneous LLC tumors; hypoxic TAMs
were sorted as before (Movahedi et al., 2010).
Migration Assays
Six-week-old mice were subcutaneously injected with 500 ml of growth factor-
reducedMatrigel (BD Biosciences), supplemented with either PBS or with 1 mg
purified murine Sema3A, VEGF164, or VEGF120 (R&D). After 5 days, mice were
sacrificed and macrophage recruitment was evaluated by histological anal-
ysis. Skin inflammation was induced by ear painting with the phorbol ester
TPA and analyzed after 24 hr.
Endothelial Cell Capillary Formation
Sorted TAMs or 105 BMDMs were embedded in growth factor-reduced Matri-
gel (BD Biosciences). After 36 hr, 104 human umbilical vein endothelial cells
(HUVECs) fluorescently labeled with PKH-26 (Sigma-Aldrich) were added to
the Matrigel. Alternatively, a conditioned medium (obtained from 2.5 3 105
BMDMs or sorted TAMs in culture for 36 hr) was used to resuspend 104
HUVECs, which were then seeded directly on Matrigel. After 4 hr, capillary
formation was analyzed by measuring the number of branches and length of
the vascular network using ImageJ software.
Macrophage Cytotoxicity Assay
LLC cells were labeled with 1 mCi/ml 3H-Thymidine for 20 hr. Then, 104 cells
were seeded together with increasing concentrations of activated BMDMs
(20 ng/ml IFNg + 100 ng/ml lipopolysaccharide for 24 hr) or sorted TAMs. After
24 hr, LLC cell death was detected by measuring radioactivity in a cell-free
medium.
T Cell Suppression
For T cell suppression, 2 3 105 naive C57BL/6 splenocytes were added to
increasing concentrations of BMDMs or sorted TAMs, and stimulated with
1 mg/ml anti-CD3. After 24 hr, cells were pulsedwith 3H-thymidine (PerkinElmer)
and incubated for another 18 hr before incorporated radioactivity was
measured.
T Cell Depletion
Th-cell and CTL depletion was performed in LLC tumor-bearing mice with
intraperitoneal injection of 0.2 mg anti-CD4 (GK1.5) or anti-CD8 (53-6.7;
BioXCell), respectively, or rat IgG isotypes as control, every third day, starting
the sixth day after tumor injection.
Statistics
Data indicate mean ± SEM of representative experiments. Statistical sig-
nificance was calculated by two-tailed unpaired t test for two data sets (or
Chi-square for PyMT tumor staging and Gehan-Breslow-Wilcoxon for the
survival upon orthotopic LLC tumor implantation), with p < 0.05 considered
as statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2013.11.007.
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